Literature DB >> 10761558

[Drug-induced gynecomastia].

F C Hugues1, C Gourlot, C Le Jeunne.   

Abstract

Drugs are a very common cause of gynecomastia and should always be entertained as the possible causal agent of such a condition. This drug side-effect is due to an impaired balance in the serum estrogen/serum androgen ratio, whatever the mechanism, or a rise in prolactin level. Sex hormones, antiandrogens, are frequently involved as well as spironolactone, cimetidine, verapamil and cancer chemotherapy (especially alkylating agents). Diazepam, tricyclic antidepressants, neuroleptics, calcium channel blockers, captopril, digitalis glycosides, omeprazole, some antibiotics and growth hormone are all possibly, but less often, the responsible agent. Criteria of the French method for determining drug causality are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761558

Source DB:  PubMed          Journal:  Ann Med Interne (Paris)        ISSN: 0003-410X


  5 in total

1.  Influence of cimetidine and bromocriptine on prolactin levels in rat fertility.

Authors:  Qamar Hamid; Sadaf Hamid; Liaqat Ali Minhas; Anjuman Gul
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2008-10-30

Review 2.  Mineralocorticoids and Cardiovascular Disease in Females with Insulin Resistance and Obesity.

Authors:  Manav Nayyar; Guido Lastra; Camila Manrique Acevedo
Journal:  Curr Hypertens Rep       Date:  2018-08-14       Impact factor: 5.369

3.  Male gynecomastia and risk for malignant tumours--a cohort study.

Authors:  H Olsson; A Bladstrom; P Alm
Journal:  BMC Cancer       Date:  2002-10-16       Impact factor: 4.430

4.  A rare case of unilateral gynecomastia during antituberculous chemotherapy with isoniazid.

Authors:  B K Manjunatha Goud; Oinam Sarsina Devi; Bhavna Nayal; R N Devaki
Journal:  Indian J Pharmacol       Date:  2012 Jul-Aug       Impact factor: 1.200

5.  Characterizing the network of drugs and their affected metabolic subpathways.

Authors:  Chunquan Li; Desi Shang; Yan Wang; Jing Li; Junwei Han; Shuyuan Wang; Qianlan Yao; Yingying Wang; Yunpeng Zhang; Chunlong Zhang; Yanjun Xu; Wei Jiang; Xia Li
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.